Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Dec. 9, 2011 - PRLog -- GlobalData estimates the global epilepsy therapeutics market to be worth $2.9 billion in 2010, and is forecast to register slow growth, with a Compound Annual Growth Rate (CAGR) of 3.5% annually to reach $3.8 billion by 2018. Generic erosion of the leading second generation antiepileptic drugs (AEDs) such as Keppra (levetiracetam), Lamictal (lamotrigine), Topamax (topiramate) and so on is the major factor for the slow growth of the epilepsy therapeutics market during the forecast period. The market is forecast to register a decline due to competition from generics which is predicted to increase over the coming years. The increasing market penetration and availability of generics is likely to act as a barrier for future market players. The introduction and patent expiry of drugs such as Keppra, Lamictal and Topamax across the seven major markets (the US, the UK, France, Germany, Spain, Italy and Japan) at various times resulted in a CAGR of 5.3% during the period 2005-2010. The launch of new drugs such as Potiga /Trobalt (ezogabine/retigabine), brivaracetam and Stedesa (eslicarbazepine acetate) (in the US) offering better efficacy and safety are expected to sustain positive growth through to 2018. Trobalt or Potiga has the non-propriety name ezogabine in the US and retigabine in the rest of the world.

The epilepsy market has moderate unmet needs. Several AEDs have become available over the past 15 years. The AED market is currently under pressure from generic competition, the generic drugs are typically priced at 40-50% lower prices than their branded counterparts. However, currently available medication is not only used for epilepsy but also for other conditions such as neuropathic pain, fibromyalgia, migraine and so on. The possible approval of AEDs for new indications such as their use as monotherapy for refractory epilepsy will potentially provide growth for the epilepsy therapeutics market. At present, more than 50% of epilepsy patients become seizure-free with the currently prescribed AEDs. This suggests that there is still scope for new market entrants targeting superior efficacy and safety. Overall, across all types of seizure disorders, approximately 30% of patients are still not seizure-free, despite the availability of many AEDs.

GlobalData suggests the current market competition is strong and that the marketed products are partially successful in meeting the needs of the patient. The current market is crowded and driven by generic substitutes, me-too products, and product extensions. This scenario enables the entrance of cheaper alternatives into the market. However, globally, nearly 30% of patients still suffer from secondary and primary seizures even while continuing with medication.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

The assessment of the current epilepsy therapeutics market suggests that the market is dominated by large multinationals such as UCB, Supernus Pharmaceuticals, GlaxoSmithKline (GSK), Pfizer, Sunovion, and Johnson & Johnson. These companies market the leading brands such as Keppra, Lamictal, Lyrica (pregabalin) and Topamax.

The analysis of the developmental pipeline suggests that these leading participants of the market are likely to maintain their position in the epilepsy therapeutics market through to 2018. However, Lundbeck and Novartis AG also have a single molecule each in development for epilepsy. Many pharmaceutical manufactures are in the process of developing novel therapeutics with extensive R&D projects focusing on “refractory epilepsy” (epilepsy which cannot be controlled by drug therapy) which is a potentially lucrative market.

GlobalData, the industry analysis specialist, has released its new report, “Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global epilepsy therapeutics market, identifying the key trends shaping and driving the global epilepsy market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global epilepsy sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Epil...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.